Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care

摘要: While personalised cancer medicine holds great promise, targeting therapies to the biological characteristics of patients is limited by number validated biomarkers currently available. The implementation has undergone many challenges with few reaching in clinic. There have been that published and claimed be therapeutically useful, but become part clinical decision-making process due technical, validation market access issues. To reduce this attrition rate, there a significant need for policy makers reimbursement agencies define specific evidence requirements introduction into practice. Once these are more clearly defined, an analogous manner pharmaceuticals, researchers diagnostic companies can better focus their biomarker research development on meeting requirements, which should lead rapid new molecular oncology tests patient benefit.